ERBB3 EXPRESSION ASSESSED BY IMMUNOHISTOCHEMISTRY (IHC) IN NON-SMALL CELL LUNG CANCER (NSCLC) TUMORS WITH EGFR MUTATION, BEFORE EGFR-TYROSINE-KINASE INHIBITOR (EGFR-TKI) EXPOSURE

被引：0
|
作者：
Felip, Enriqueta [1 ]
Hernandez-Losa, Javier [2 ]
Murtra-Garrell, Nuria [1 ]
Freixinos, Victor [1 ]
Salcedo, Maite [2 ]
Tallada, Natalia [2 ]
Teixido, Cristina [2 ]
Martinez, Pablo [1 ]
Cedres, Susana [1 ]
Lopez, Eva [3 ]
Pandielle, Anastasio
Cajal, Santiago Ramon Y. [2 ]
机构：
[1] Vall Hebron Univ Hosp, Dept Oncol, Barcelona, Spain
[2] Vall Hebron Univ Hosp, Dept Pathol, Barcelona, Spain
[3] Vall Hebron Hosp, Dept Stat, Barcelona, Spain
来源：
JOURNAL OF THORACIC ONCOLOGY | 2011年 / 6卷 / 06期
关键词：
EGFR mutation; ErbB3;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S1104 / S1105
页数：2
相关论文
共 50 条
  • [21] Impact of EGFR-TKI Treatment on the Tumor Immune Microenvironment in EGFR Mutation-Positive Non-Small Cell Lung Cancer
    Isomoto, Kohsuke
    Haratani, Koji
    Hayashi, Hidetoshi
    Shimizu, Shigeki
    Tomida, Shuta
    Niwa, Takashi
    Yokoyama, Toshihide
    Fukuda, Yasushi
    Chiba, Yasutaka
    Kato, Ryoji
    Tanizaki, Junko
    Tanaka, Kaoru
    Takeda, Masayuki
    Ogura, Takashi
    Ishida, Tadashi
    Ito, Akihiko
    Nakagawa, Kazuhiko
    CLINICAL CANCER RESEARCH, 2020, 26 (08) : 2037 - 2046
  • [22] Mechanisms of EGFR-TKI induced cell death and resistance in EGFR mutant non-small cell lung cancer
    Ko, J.
    Kim, Y.
    Park, M.
    Cui, Z.
    Ahn, M.
    Park, K.
    EJC SUPPLEMENTS, 2008, 6 (09): : 29 - 30
  • [23] Cytokeratin 19 fragment (CYFRA21-1) to predict the efficacy of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) in non-small cell lung cancer (NSCLC) harboring EGFR mutation
    Tanaka, Kosuke
    Hata, Akito
    Kaji, Reiko
    Fujita, Shiro
    Takeshita, Jumpei
    Matsumoto, Takeshi
    Monden, Kazuya
    Nagata, Kazuma
    Otsuka, Kyoko
    Nanjo, Shigeki
    Tachikawa, Ryo
    Otsuka, Kojiro
    Hayashi, Michio
    Tomii, Keisuke
    Katakami, Nobuyuki
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [24] EGFR tyrosine kinase inhibitor in advanced non-small cell lung cancer with wild-type EGFR
    Wang, Z.
    Wu, Y. L.
    Yang, J.
    Wang, B.
    Huang, Y.
    Zhou, Q.
    Xu, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [25] Effect of hydrothorax EGFR gene mutation and EGFR-TKI targeted therapy on advanced non-small cell lung cancer patients
    Zhou, Bo
    Nie, Jun
    Yang, Weidong
    Huang, Chenhong
    Huang, Ye
    Zhao, Hongfei
    ONCOLOGY LETTERS, 2016, 11 (02) : 1413 - 1417
  • [26] A Phase lb Study of the Combination of Afatinib and Ruxolitinib in EGFR Mutant Non-Small Cell Lung Cancer (NSCLC) Progressed on EGFR-TKI
    Park, Ji Soo
    Kim, Hye Ryun
    Hong, Min Hee
    Cho, Byoung Chul
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1069 - S1070
  • [27] Immunohistochemistry (IHC) with EGFR mutation-specific monoclonal antibodies (mAbs) for screening EGFR mutations in non-small cell lung cancer (NSCLC) patients (p)
    Simonetti, S.
    Molina, M. A.
    Mayo, C.
    Bertzan-Alamillo, J.
    Moran, T.
    Benlloch, S.
    Ramon y Cajal, S.
    Wistuba, I. I.
    Taron, M.
    Rosell, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [28] Effect of EGFR-TKI retreatment following chemotherapy for advanced non-small cell lung cancer patients who underwent EGFR-TKI
    Guo-Hao Xia
    Yun Zeng
    Ying Fang
    Shao-Rong Yu
    Li Wang
    Mei-Qi Shi
    Wei-Li Sun
    Xin-En Huang
    Jia Chen
    Ji- Feng Feng
    Cancer Biology & Medicine, 2014, (04) : 270 - 276
  • [29] EGFR Protein Expression in Non-Small Cell Lung Cancer Predicts Response to an EGFR Tyrosine Kinase Inhibitor-A Novel Antibody for Immunohistochemistry or AQUA Technology
    Mascaux, Celine
    Wynes, Murry W.
    Kato, Yasufumi
    Tran, Cindy
    Asuncion, Bernadette Reyna
    Zhao, Jason M.
    Gustavson, Mark
    Ranger-Moore, Jim
    Gaire, Fabien
    Matsubayashi, Jun
    Nagao, Toshitaka
    Yoshida, Koichi
    Ohira, Tatuso
    Ikeda, Norihiko
    Hirsch, Fred R.
    CLINICAL CANCER RESEARCH, 2011, 17 (24) : 7796 - 7807
  • [30] Efficacy and safety of apatinib plus EGFR-TKI in advanced non-small cell lung cancer with EGFR-TKI resistance (date updated)
    Tian, R.
    Guo, W.
    Guo, Y.
    Zhang, X.
    Zhu, H.
    Shen, F.
    Zhang, X.
    Wang, R.
    Ren, X.
    Li, J.
    Song, X.
    ANNALS OF ONCOLOGY, 2020, 31 : S873 - S873
12345